Clinical Efficacy of Prodom-Assisted Urokinase in the Treatment of Male Infertility Caused by Impaired Semen Liquefaction

Purpose. To evaluate the clinical efficacy of prodom in the administration of urokinase in the vagina in couples with impaired semen liquefaction. Materials and Methods. Overall, 261 patients with impaired semen liquefaction were randomly divided into prodom-assisted urokinase treatment (PAUT) group...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2021, Vol.2021 (1), p.8862282-8862282
Main Authors: Mao, Kaiyi, Chen, Zongping, Li, Mengzhi, Gou, Chengren, Zhou, Zidong, Yan, Yong, Chen, Chao, Liu, Tong, Zou, Chenghong, Yao, Yuhong, Li, Xu
Format: Article
Language:English
Subjects:
Adult
Care and treatment
Causes of
Costs
Dosage and administration
Endocrinology
Female
Gene expression
Humans
Infertility
Infertility, Male
Infertility, Male - drug therapy
Infertility, Male - metabolism
Infertility, Male - pathology
Liquefaction
Male
Middle Aged
Motility
Patient outcomes
Patients
Penis
Pregnancy
Pregnancy Rate
Semen
Semen - chemistry
Semen - drug effects
Semen - physiology
Sperm
Sperm Count
Sperm Motility - physiology
Thrombolytic drugs
Thrombosis
U-Plasminogen activator
Urokinase
Urokinase-Type Plasminogen Activator - administration & dosage
Vagina
Vagina - physiology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose. To evaluate the clinical efficacy of prodom in the administration of urokinase in the vagina in couples with impaired semen liquefaction. Materials and Methods. Overall, 261 patients with impaired semen liquefaction were randomly divided into prodom-assisted urokinase treatment (PAUT) group (n=91), syringe-assisted urokinase treatment (SAUT) group (n=86), and traditional treatment (TT) group (n=84) in the first stage. If the first stage of treatment failed, other treatment methods were initiated instead and the patients were grouped according to the newer treatment method in the second stage. The pregnancy rate, time-to-conception, and treatment costs were evaluated in each group. Results. In the first stage, the pregnancy rate in the PAUT, SAUT, and TT groups was 69.23%, 29.07%, and 22.62%, respectively; the time-to-conception was 2.66±1.44, 3.69±2.61, and 3.86±3.00 months, respectively; the treatment costs were 658.18±398.40, 666.67±507.50, and 680.56±480.94 $, respectively. The pregnancy rate and time-to-conception were different in the PAUT group compared with those in SAUT and TT groups (all P
ISSN:2314-6133
2314-6141
DOI:10.1155/2021/8862282